Lemtrada (Campath) appears to help MS patients in study

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Lemtrada (Campath) appears to help MS patients in study

Postby MSUK » Mon Oct 24, 2011 12:23 am


New data from a late-stage trial showed that 78 percent of patients treated with Lemtrada remained relapse-free for two years, compared with 59 percent using Rebif, an older multiple sclerosis drug sold by Germany's Merck.

Lemtrada is a key experimental product at Sanofi's Genzyme unit. The fortunes of the drug are closely watched by holders of Genzyme Contingent Value Rights certificates issued to shareholders as part of the U.S. company's takeover deal.

CVRs represent an extra fee holders will receive if Lemtrada hits certain targets or when Genzyme meets other milestones.

The commercial potential of the drug, already sold under the brand name Campath as a leukemia treatment, was a key bone of contention between Sanofi and Genzyme during takeover talks.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1307
MS-UK - http://www.ms-uk.org/
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 3:00 pm


Return to Campath (Lemtrada, Alemtuzumab)


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service